Kornimate/medical-research-clean huggingface dataset:
effect of early oral triple viable bifidobacterium intestinal flora in preterm

Conditions: Disorder of Stomach Function and Feeding Problems in Newborn; Feeding and Eating Disorders of Childhood

Summary: gut of newborn preterm is sterile, immediately by the mother and the surrounding environment from microbial colonization. as the effects of diet, intestinal flora is rapidly changed. preterm children significantly delay in the establishment of normal flora,during hospitalization because of no breastfeeding, use of antibiotics, enteral feeding delay, combat disease and other factors. in this study, hospitalized preterm children for the study, the prospective randomized double-blind controlled study, to find oral intestinal bifidobacteria and lactobacilli and bifidobacteria subspecies composition and distribution, and further show intestinal bacteria in premature children case group.

preterm infants are at high risk of deeding intolerance especially low birth weight infants, whether oral triple viable bifidobacterium and early micro-feeding may improve the symptoms of feeding intolerance. 84 preterm infants bw(birth weight) less than 2.5kg,entered neonatal intensive care unit(nicu) less than 24 hours and meet the inclusion criteria of this study will be randomly divided into three groups, control group、 treatment group1 (triple viable bifidobacterium 0.5g bid po)、treatment group2 （triple viable bifidobacterium 0.5g bid po and early micro-feeding）. treatment period for more than 1 week. for three groups, feeding symptoms,the traits and frequency of stool of 3 days,1 weeks,2 weeks.and the stool flora measured by pcr.

Eligibility criteria:
inclusion criteria: * preterm with birth weight \<2.5kg exclusion criteria: * gastrointestinal bleeding and nec,kidney,liver function abnormal and have serious congenital malformation

Keywords: preterm; intestinal flora; early micro-feeding feeding intolerance
non-invasive haemodynamic monitoring in pregnancy

Conditions: Pregnancy Related; Cardiac Output, High; Haemodynamic Instability

Summary: this prospective and observational trial over 55 pregnant women (third trimester) compares non invasive haemodynamic monitoring using nexfin technology and ultrasonography technic


Eligibility criteria:
inclusion criteria: * third trimester of pregnancy * non-labouring pregnant women * accepting study exclusion criteria: * refusal of study * first or second trimester of pregnancy
quality of life in presbyopes using single-vision lens and progressive lens correction

Conditions: Presbyopia; Presbyopia Correction

Summary: the goal of this clinical trial is to compare the quality of life (qol) of presbyopes wearing progressive addition lenses (pals) with that of those wearing single-vision spectacles (svss) for near correction. the main questions it aims to answer is: what is the difference in qol between presbyopes who use svss and those who use pals ? eligible participants will be randomly assigned in a 1:1 ratio to either the pals group or the svss group.participants in the progressive lenses intervention group will receive 1-month progressive lens correction in daily life. and participants in single-vision lenses intervention group will use near-vision spectacles during near work and use their original habitual distant glasses for distance tasks for 1 month. the study will compare the qol scores measured by a 12-item near vision-related quality of life questionnaire between the two groups. additionally, the study will compare the scores measured by the refractive status and vision profile questionnaire and visual analogue scale questionnaire between the two groups as well as assess the change in the above three questionnaires scores at 1 month following enrollment. and visual acuity of subjects will also be assessed at baseline and at the 1-month follow-up.


Eligibility criteria:
inclusion criteria: 1. age 40-70 years; 2. a distant correction of ≤2d for hyperopia, or \>-2 d for myopia, or \< 2d for astigmatism in both eyes; 3. anisometropia of less than 1.50 d; 4. distance best-corrected visual acuity (bcva) of at least 0.5 logmar, and near va \< n8 (20/50) at 40 cm with habitually worn distance refractive correction, with improvement of near vision by at least one line on a near logmar e chart with the use of a plus lens; 5. have not undergone any near correction in the past six months; 6. able to answer a questionnaire; 7. giving written consent to participate in the study. exclusion criteria: 1. ocular abnormalities leading to visual impairment including severe cataract, glaucoma, strabismus, and ocular fundus diseases; 2. severe physiological and psychological diseases affecting follow-up; 3. history of cataract surgery, phakic intraocular lens surgery, corneal surgery, or any intraocular surgery affecting the refractive status of the eye; 4. have used pilocarpine in the past six months.

Keywords: quality of life presbyopia near correction
effect of variance on error correction during coupling

Conditions: Multiple Sclerosis; Progressive Multiple Sclerosis

Summary: this study is a case-control study, involving persons with progressive multiple sclerosis and healthy controls. the study contains 1 descriptive and 3 experimental sessions. in the descriptive session, participant's clinical motor and cognitive functions are collected. in the first experimental session, participant's beat perception and synchronisation abilities is examined within a finger tapping paradigm. in the following experimental sessions participants synchronsiation abilities is examined during walking paradigms, to music and metronomes, with period and phase auditory manipulations. in the latter twp sessions, apart from outcome measures of synchronization the following will be collected as well: brain activity using eeg recordings, spatio-temporal gait parameters, perceived fatigue, perceived motivation and perceived speed of walking.


Eligibility criteria:
inclusion criteria: * diagnosis of multiple sclerosis \>1 year, diagnosis of progressive ms, * walking speed 0.8-1.2m/s, ability to walk for 6 minutes continuously (canes and rollators are permitted) exclusion criteria: * relapse 3 months prior to enrollment, * cognitive impairment impeding understanding of instructions, * beat amusia, * deafness, * pregnancy
fasted exercise in people with type 1 diabetes

Conditions: Type1diabetes

Summary: this study aims to compare the effect of a bout of high-intensity interval training (hit) with a bout of moderate-intensity continuous training (mict) on glucose concentrations over the subsequent 24h period.

this study aims to compare the effect of a bout of high-intensity interval training (hit) with a bout of moderate-intensity continuous training (mict) on glucose concentrations over the subsequent 24h period. fourteen people with type 1 diabetes (duration of type 1 diabetes 8.2±1.4 years), all on basal-bolus regimen, completed a randomised, counterbalanced, crossover study. continuous glucose monitoring was used to assess glycaemic control following a single bout of hit (6 x 1min intervals) and 30 mins of moderate-intensity continuous training (mict) on separate days, compared to a non-exercise control day (con). exercise was undertaken following an overnight fast with omission of short-acting insulin. capillary blood glucose samples were recorded pre and post-exercise to assess the acute changes in glycaemia during hit and mict.

Eligibility criteria:
inclusion criteria: * duration of type 1 diabetes \>6 months * basal bolus regimen * no significant history of hyper- or hypoglycaemia (determined from medical history exclusion criteria: * duration of type 1 diabetes \<6 months, * insulin pump therapy * significant history of hyper- or hypoglycaemia (determined from medical history) * obesity (bmi \>30 kg∙m-2) * pregnancy or planning pregnancy, uncontrolled hypertension (\>180/100 mmhg) * angina * autonomic neuropathy * taking any medication that affects heart rate * major surgery planned within 6 weeks of the study * severe nonproliferative and * unstable proliferative retinopathy
efficacy evaluation of an odf iron supplement vs an iron supplement in capsules in subjects with mild anemia

Conditions: Iron Deficiencies

Summary: the aim of the study is to evaluate the efficacy of a new iron supplement with orodispersible formulation vs an iron supplement in capsules in subjects with mild anemia.

the aim of the study is to evaluate the efficacy of a new iron supplement with orodispersible formulation in modulating peripheral blood biomarkers of iron levels in subjects with mild anemia after 8 weeks of supplementation, compared to baseline values and also aims to evaluate its acceptability. for the evaluation, an iron supplement in capsules will be used as a comparison supplement.

Eligibility criteria:
inclusion criteria: * written informed consent signed prior to inclusion in the study * 18-55 years * ability to understand the nature and the purpose of the study, including possible risks and side effects * capability to collaborate with the investigator and meet the requirements of the entire study * subjects with mild anemia (with who hemoglobin values between 11-11.9 g/dl for women and between 11-12.9 g/dl for men) exclusion criteria: * clinically significant abnormalities in the ecg evaluation * clinically significant abnormal laboratory values indicative of disease * known allergy or presumed hypersensitivity to the food supplement investigated (iron) and / or to the excipients of the two formulations * history of anaphylaxis from drugs, dietary supplements or allergic reactions in general, which the investigator believed could influence the outcome of the study * significant history of kidney, liver, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases that may interfere with the purpose of the study * taking herbal remedies and dietary supplements (including iron supplements, supplements with vitamin c, supplements with folic acid, supplements with vitamin b12, multivitamins) in the 2 weeks prior to the start of the study * taking corticosteroids, thyroid hormones, antibiotics, antiepileptics * alcohol abuse * any clinical condition that in the investigator's judgment is deemed incompatible with study participation * women who are pregnant or breastfeeding
weight-loss drug for fertility-sparing treatment of atypical hyperplasia and low-grade cancer of the endometrium

Conditions: Endometrial Cancer; Atypical Hyperplasia

Summary: the incidence of endometrial cancer is increasing at an alarming rate. this trend parallels the rising rate of obesity, the most significant risk factor for endometrial cancer. young women with obesity and endometrial cancer or atypical hyperplasia who want to maintain their fertility are treated with progestin therapy, such as progestin intra-uterine device (piud), which is associated with a mediocre response rate and high recurrence rate, and does not address the underlying cause, obesity. therefore, the investigators want to assess whether the addition of a weight-loss drug to piud will improve their oncologic, reproductive and metabolic outcomes.

the research aims to answer the question: "does the addition of a glucose-dependent insulinotropic polypeptide (gip)/glucagon-like peptide-1 (glp-1) co-agonist to standard progestin treatment lead to a higher complete response rate compared to historical response rates using progestin alone in young patients with endometrial cancer/atypical hyperplasia who wish to preserve their fertility?". this is a multicentre single arm open-label phase ii clinical trial to assess the complete pathologic response as determined by endometrial sampling after 48 weeks of tirzepatide (gip/glp-1 co-agonist) and progestin therapy in patients with bmi ≥ 27 who have endometrial cancer/atypical hyperplasia and desire fertility preservation.

Eligibility criteria:
inclusion criteria: * bmi ≥ 27 * diagnosis of grade 1 or 2 endometrioid endometrial cancer or atypical hyperplasia made by either endometrial biopsy or dilation and curettage * for those with endometrial cancer, clinical figo 2009 stage 1a disease without evidence of metastatic disease beyond the uterus and no myometrial invasion by mri or ct * ecog status \<2 * desire for fertility preservation * ability to understand and willing to sign a written informed consent document exclusion criteria: * evidence of myometrial invasion or extra-uterine disease on imaging * high grade or p53 mutated (p53mut) endometrial cancer * estrogen receptor negative endometrial cancer (positivity defined as moderate/strong staining\>10%) * mismatch repair deficient (mmrd) endometrial cancer * history of other malignancies except if curatively treated with no evidence of disease for \>5 years * previous surgical treatment of obesity * current use of weight loss medication (no use in last 2 months) * medical co-morbidity with end-organ dysfunction * contraindications to piud or tirzepatide. * any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.

Keywords: tirzepatide piud
eight units extended maxillary fixed retainer

Conditions: Orthodontic Retention

Summary: assessment of dental changes associated with an eight-unit extended maxillary fixed retainer in 3d. monitoring pdl response and evaluation of patient's satisfaction ,quality of life and speech with extended maxillary fixed retainer

single-arm prospective clinical trial will be conducted to assess of dental changes associated with an eight-unit extended maxillary fixed retainer in 3d. monitoring pdl response and evaluation of patient's satisfaction ,quality of life and speech with extended maxillary fixed retainer. . twenty-six patients who finished the active orthodontic treatment phase (14-28 years) will be recruited upon complying with the inclusion criteria. eight-unit extended maxillary fixed retainer will be bonded to palatal surface of maxillary incisors, canines and first premolars, pdl assessment will be carried out and patient acceptance to the appliance through the valid questionnaire then the patients will be followed up for 6 months to document 3d post-treatment changes.

Eligibility criteria:
inclusion criteria: * patients who finished the active orthodontic treatment and started the retention phase. * both genders. * extraction and non-extraction cases exclusion criteria: * patients who had active transverse palatal expansion. * patients with active periodontal disease. * patients with systemic disease and bone diseases, or craniofacial syndromes, or the presence of cleft. * patients with abnormal surface or morphological tooth structure or restorations.

Keywords: extended fixed retainer 3d superimposition fixed retainers pdl quality of life relapse
a study in korea of entecavir versus lamivudine in adults with chronic hepatitis b infection

Conditions: Chronic Hepatitis B

Summary: entecavir, 0.5 mg daily, will have clinical efficacy (assessed as an undetectable hepatitis b dna, \<300 copies/ml, by roche comprehensive bio-analytical system amplicor polymerase chain reaction assay) that is comparable (noninferior) and potentially superior to lamivudine, 100 mg once daily, in adults with hepatitis b e antigen-negative chronic hepatitis b virus infection.


Eligibility criteria:
inclusion criteria: * nucleoside and nucleotide-naive subjects with chronic hbv infection * hepatitis b surface antigen(hbsag)-positive ≥6 months * detectable hbsag * hbv dna ≥ 105 copies/ml by pcr * alt 1.3 to 10 x the uln * hbeag negative, anti-hepatitis b virus e antigen antibody (anti-hbeab) positive status
safety and immunogenicity of fluzone® vaccine in children who received 2 doses of the 2005-2006 fluzone formulation.

Conditions: Influenza

Summary: to compare the groups with respect to influenza immune responses following dose 1 of fluzone vaccine (2006-2007 formulation).


Eligibility criteria:
inclusion criteria : * previously enrolled in study grc28 and received 2 vaccinations of the assigned lot. * considered to be in good health on the basis of reported medical history and history-directed physical evaluation. * available for the duration of the study. * parent/legal representative willing and able to provide informed consent. * parent/legal representative able to attend all scheduled visits and comply with all trial procedures. * parent/legal representative willing to permit venipuncture for purposes of collecting a blood sample. exclusion criteria : * receipt of any vaccine within the past 7 days (subjects may be deferred until after the seven days has passed.) * reported allergy to egg proteins, chicken proteins or any other constituent of the vaccine. * ever received any influenza vaccine, other than at visits 1 and 2 of study grc28, or known to have ever been diagnosed with laboratory-confirmed influenza. * an acute illness with fever (rectal temperature ≥ 100.4°f \[38.0°c\]) in the 72 hours preceding enrollment in the trial (defer enrollment). * known bleeding disorder. * participation in any other interventional clinical trial within 30 days prior to enrollment, or planned participation in another interventional clinical trial prior to termination of the subject's participation in the study. * known or suspected impairment of immunologic function or receipt of immunosuppressive therapy or immunoglobulin since birth. * personal or immediate family history of congenital immune deficiency. * developmental delay, neurologic disorder, or seizure disorder. * chronic medical, congenital, or developmental disorder that, in the opinion of the investigator, could interfere with trial conduct or completion. * known human immunodeficiency virus (hiv)-positive mother or hepatitis b surface antigen (hbsag)-positive mother. * known hiv, hepatitis b, or hepatitis c infection. * administration of immune globulin or other blood products within the last three months, or injected or oral corticosteroids or other immunomodulator therapy within six weeks of the study vaccine. individuals on a tapering dose schedule of oral steroids lasting \< 7 days may be included in the trial as long as they have not received more than one course within the last two weeks prior to enrollment. * prior personal history of guillain-barré syndrome. * any condition that, in the opinion of the investigator, would pose a health risk to the subject or interfere with the evaluation of the vaccine.

Keywords: fluzone® influenza influenza virus infection influenza vaccine
the effect of perineal wound infection on the anal sphincter

Conditions: Obstetric Trauma; Perineum; Injury; Perineal Infection; Anal Sphincter Injury

Summary: perineal injury following childbirth can result in complications such as wound infection. the perineum has closely related anatomical structures including the external genital organs and the anal triangle which contains the anal sphincter muscles. therefore as wound infection can extend and as muscles of the perineum sit in such close proximity to each other, the anal sphincter muscles could potentially be affected. this could also potentially include cases of perineal injury where the anal sphincter was not injured. however ultrasound has never been used to investigate this. endoanal ultrasound is the gold standard diagnostic tool in the assessment of obstetric anal sphincter injury. the anal sphincter can also be visualised using multiplanar transperineal ultrasound(three/four-dimensional. therefore both modalities could be used. however, it has been shown that transperineal ultrasound has a high positive predictive value and therefore is able to correctly identify an intact anal sphincter, but low positive predictive value; meaning poor detection of sphincter defects. therefore, although it cannot completely substitute endoanal ultrasound (the gold standard in investigating obstetric anal sphincter injuries), it provides and adjunct/alternative for women who cannot tolerate endoanal ultrasound. the investigators plan to perform an observational study to evaluate to the natural history of perineal wound infections. patients will be assessed weekly with endoanal ultrasound and/or transperineal ultrasound until the wound infection has resolved and the wound has clinically healed. if a bacterial wound swab has not been taken prior to recruitment or wound swab results are not available, one will be taken to detect the causative organisms. appropriate antibiotics will then be given to cover the detected organism. bacterial burden and will also be measured weekly using the moleculight i:x; a bacterial autofluorescence camera which captures the presence and load of bacteria. in wounds that have superficially dehisced; exact wound measurements including wound surface area, depth, volume and healing progress will be precisely measured using the silhouette® 3d camera


Eligibility criteria:
inclusion criteria: * women with childbirth related perineal injury and wound infection * women over 18 years of age * ability to understand and read the patient information sheet (in english) * ability to give informed consent exclusion criteria: * vulnerable adult * fetal or neonatal death or poor neonatal outcome * women who are in an immunosuppressive state (e.g human immunodeficiency virus or pharmacologically induced immunodeficiencies by chemotherapy or steroids) * inability to give consent

Keywords: obstetric anal sphincter injury childbirth related perineal trauma perineal wound infection endoanal ultrasound transperineal ultrasound 3d ultrasound 4d ultrasound
community organizing network for environmental health

Conditions: Asthma

Summary: the community organizing network for environmental health is a part of community action against asthma (caaa), which, in turn is a part of the michigan center for the environment and children's health. it is a community-based intervention research partnership between the university of michigan, community-based organizations, and health care institutions in detroit.

the aims of the community organizing network for environmental health are to: * share with community groups and organizations the findings from data collected through household and air quality research of the caaa project; * identify and engage existing community groups and organizations interested in working on environmental issues important to their neighborhood and community in the hopes of creating an interorganizational network (i.n.); * work with member group of the i.n. to organize, coordinate and conduct activities to reduce physical environmental threats related to asthma; and * increase community awareness and knowledge of factors associated with the environment and asthma through sharing of findings to community residents through presentations, annual reports, postings of websites, and community forums

Eligibility criteria:

Keywords: asthma children's health community based research
learning enhancement through neurostimulation in autism

Conditions: Autism

Summary: this study will examine whether brain stimulation paired with social skills learning can help teenage boys with autism learn how to make and keep friends. brain stimulation can enhance learning in some people. this study involves enrolling in a 14-week training program where teenage boys with autism interact in small groups and learn social skills. during the 14-week program participants will receive active brain stimulation, or non-active stimulation (placebo). before and after this training, mri scans will be taken to see whether the training with active brain stimulation made a different in brain activation.


Eligibility criteria:
inclusion criteria: * autism spectrum disorder exclusion criteria: * intellectual disabilities (full-scale iq \<70) * hx of seizures within the last one year * contraindications for fmri, such as metal implants in the head

Keywords: autism adolescent social skills